Niger, AVENIR
AVENIR is an adaptive cluster-randomized trial designed to determine the impact of age-based targeting of azithromycin mass drug administration on mortality and antimicrobial resistance outcomes
Design
Cluster-randomized, placebo-controlled, double-masked, response-adaptive large simple trial
Key evaluations
Age targeting (1–11 vs. 1–59 months); feasibility at scale.
Outcomes
All-cause mortality rate after 2.5 years in:
1. children 1–59 months old comparing the azithromycin 1–59 and placebo arms
2. children 1–11 months old comparing the azithromycin 1–11 and placebo arms, and
3. children 12–59 months in the azithromycin 1–11 and azithromycin 1–59 arms.
AMR: primary resistance outcomes will be assessed after 2 years of distributions and include:
1. prevalence of genetic determinants of macrolide resistance in nasopharyngeal samples from children 1–59 months old, and
2. load of genetic determinants of macrolide resistance in rectal samples from children 1–59 months old.
Location
The Dosso, Tahoua, and Maradi regions of Niger
